Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies Distinct Toxicity Profiles for Anti-BCMA Myeloma Therapies

CAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news